Fernand Labrie

Publications

Page 1 of 2, showing 50 records out of 64 total, starting on record 1, ending on 50

Publication Category Year
4754. Labrie, F (2011) DHEA and Cancer Risk or Prevention? In: DHEA (Dehydroepiandrosterone) in Human Health and Aging, R.R.Watson ed., Taylor & Francis Group LLC, publishers, Chapter 12, pp: 153-172. Acolbifene 2011
354. Donet, E., Bayo, P., Calvo, E., Labrie, F., Pérez, P. (2008) Identification of novel glucocorticoid receptor-regulated genes involved in epidermal homeostasis and hair follicle differentiation. J Steroid Biochem Mol Biol, 108: 8-16. Acolbifene 2008
374. Labrie, F. (2008) Combination of Breast Cancer Prevention with Tissue-Targeted Hormone Replacement Therapy, In: Breast Cancer - Prognosis, Treatment, and Prevention, Second Edition, Pasqualini, J.R., ed., pp. 201-252. Acolbifene 2008
355. Labrie, F. (2007) Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy. Nat Clin Pract Endocrinol Metab, 3: 584-93. Acolbifene 2007
659. Sancéau, J.-Y., Larouche, D., Caron, B., Bélanger, P., Coquet, A., Bélanger, A., Labrie, F., Gauthier, S. (2007) Synthesis and deuterium labelling of the pure selective estrogen receptor modulator (SERM) acolbifene glucuronides. J. of Label Compd and Radiopharm, 50: 197-206. Acolbifene 2007
380. Labrie, F. (2006) Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA. Endocr Relat Cancer, 13: 335-355. Acolbifene 2006
661. Lemieux, C., Gélinas, Y., Lalonde, J., Labrie, F., Richard, D., Deshaies, Y. (2006) Hypocholesterolemic action of the selective estrogen receptor modulator acolbifene in intact and ovariectomized rats with diet-induced hypercholesterolemia. Metabolism, 55: 605-13. Acolbifene 2006
382. Liby, K., Rendi, M., Suh, N., Royce, D.B., Risingsong, R., Williams, C.R., Lamph, W., Labrie, F., Krajewsi, S., Xu, X., Kim, H., Brown, P., Sporn, M.B. (2006) The Combination of the Rexinoid, LG100268, and a SERM, either Arzoxifene or Acolbifene, Synergize in the Prevention and Treatment of Mammary Tumors in an Estrogen Receptor Negative Model of Breast Cancer. Clin Cancer Res, 12: 5902-5909. Acolbifene 2006
663. Gauthier, S., Cloutier, J., Dory, Y.L., Favre, A., Mailhot, J., Ouellet, C., Schwerdteeger, A., Mérand, Y., Martel, C., Simard, J., Labrie, F. (2005) Synthesis and structure-activity relationships of analogs of EM-652 (acobifene), a pure selective estrogen receptor modulator. Study of mitrogen substitution. J of Enzyme Inhibition and Medicinal Chemistry, 20: 165-177. Acolbifene 2005
664. Lemieux, C., Gélinas, Y., Lalonde, J., Labrie, F., Cianflone, K., Deshaies, Y. (2005) Hypolipidemic action of the SERM acolbifene is associated with decreased liver MTP and increased SR-B1 and LDL receptors. J. of Lipid Research, 46: 1285-94. Acolbifene 2005
665. Lemieux, C., Gélinas, Y., Lalonde, J., Labrie, F., Richard, D., Deshaies, Y. (2005) The selective estrogen receptor modulator acolbifene reduces cholesterolemia idependently of its anorectic action in control and cholesterol-fed rats. J Nutr, 135: 2225-9. Acolbifene 2005
666. Lemieux, C., Phaneuf, D., Labrie, F., Giguère, V., Richard, D., Deshaies, Y. (2005) Estrogen receptor alpha-mediated adiposity-lowering and hypocholesterolemic actions of the selective estrogen receptor modulator acolbifene. Int J Obes, 29: 1236-44. Acolbifene 2005
386. Labrie, F., Champagne, P., Labrie, C., Roy, J., Laverdiere, J., Provencher, L., Potvin, M., Drolet, Y., Pollak, M., Panasci, L., L'Espérance, B., Dufresne, J., Latreille, J., Robert, E., Samson, B., Jolivet, J., Yelle, L., Cusan, L., Diamond, P., Candas, B. (2004) Activity and safety of the orally active precursor of EM-652 (Acolbifene) in Tamoxifen-resistant breast cancer. J Clin Oncol, 22: 864-871. Acolbifene 2004
668. Sancéau, J.-Y., Labrie, F., Gauthier, S. (2004) Synthesis of 14C-labelled EM-800 (SCH 57050) and EM-652. HCI (SCH 57068. HCI, acolbifene), pure selective estrogen receptor modulators. J. of Label Compounds & Radiopharmaceuticals, 47: 741-752. Acolbifene 2004
388. Gutman, M., Couillard, C., Labrie, F., Candas, B., Labrie, C. (2003) Effect of treatment sequence with radiotherapy and the antiestrogen EM-800 on the growth of ZR-75-1 Human mammary carcinoma in nude mice. Int J Cancer, 103: 268-276. Acolbifene 2003
389. Jensen, J., Kitlen, J., Briand, P., Labrie, F., Lykkesfeldt, A.E. (2003) Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium. J. Steroid Biochem Mol Biol, 84: 469-78. Acolbifene 2003
672. Labrie, F. (2003) Extragonadal synthesis of sex steroïds: Intracrinology. Ann. Endocrinol, 64: 95-107. Acolbifene 2003
390. Labrie, F., El Alfy, M., Berger, L., Labrie, C., Martel, C., Bélanger, A., Candas, B., Pelletier, G. (2003) The combination of a novel SERM with an estrogen protects the mammary gland and uterus in a rodent model: the future of postmenopausal women's health? Endocrinology, 144: 4700-4706. Acolbifene 2003
597. Lemieux, C., Picard, F., Labrie, F., Richard, D., Deshaies, Y. (2003) The estrogen antagonist EM-652 and dehydroepiandrosterone prevent diet- and ovariectomy-induced obesity. Obes. Res., 11: 477-490. Acolbifene 2003
392. Roy, J., Couillard, C., Gutman, M., Labrie, F. (2003) A novel pure SERM achieves complete regression of the majority of human breast cancer tumors in nude mice. Breast Cancer Res Treat, 81: 223-229. Acolbifene 2003
676. Tatchum-Talom, R., Martel, C., Labrie, F., Marette, A. (2003) Acute vascular effects of the selective estrogen receptor modulator EM-652 (SCH 57068) in the rat mesenteric vascular bed. J. of the European Soc. of Cardiology, 57: 535-543. Acolbifene 2003
677. Bernardi, F., Stomati, M., Luisi, S., Pieri, M., Labrie, F., Geneazzani, A.R. (2002) Effects of the new generation selective estrogen receptor modulator EM-652 and oral administration of estradiol valerate on circulating, brain, and adrenal beta-endorphin and allopregnanolone levels in intact fertile and ovariectomized rats. Fertility and Sterility, 77: 1018-1027. Acolbifene 2002
393. Gutman, M., Couillard, S., Roy, J., Labrie, F., Candas, B., Labrie, C. (2002) Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. International Journal of Cancer, 99: 273-278. Acolbifene 2002
34. Labrie, F. (2002) Endocrine-sensitive cancers of the prostate and breast, in: Baster, J., Melmed, S. et New, M., eds: Genetics in Endocrinology, Lippincott-William and Wilkins, pp 607-661. Acolbifene 2002
395. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Labrie, C. (2002) DHEA replacement therapy as a source of androgens and estrogens at menopause, in: Genazzani, A.R., Petraglia, F. et Artini, P.G., eds: Advances in Gynecological Endocrinology, Florence, Italy, Parthenon Publishing, pp 249-258. Acolbifene 2002
396. Labrie, F., Labrie, C., Bélanger, A., Simard, J. (2002) Third and fourth generation SERMs, in: Manni, A. et Verderame, M., eds: Selective Estrogen Receptor Modulators: Research and Clinical Applications, Totowa, NJ, Humana Press Inc., pp 167-187. Acolbifene 2002
682. Simoncini, T., Varone, G., Fornari, L., Mannella, P., Labrie, F., Genazzani, A.R. (2002) Genomic and non-genomic mechanisms of nitric oxide synthesis induction in human endothelial cells by a fourth generation selective estrogen receptor modulator. J. Endocrinol, 143: 2052-2061. Acolbifene 2002
669. Barbier, O., Albert, C., Martineau, I., Vallée, M., High, K., Labrie, F., Hum, D.W., Labrie, C., Bélanger, A. (2003) Glucuronidation of the nonsteroidal antiestrogen EM-652 (SCH 57068) by human and monkey steroid conjugating UDP-glucuronosyltransferase enzymes. Mol Pharmacol, 59: 636-45. Acolbifene 2001
400. Labrie, F., Labrie, C., Bélanger, A., Giguère, V., Simard, J., Mérand, Y., Gauthier, S., Luu-The, V., Candas, B., Martel, C.E.A. (2001) Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities, in: Scolnick, E.M., ed. Advances in Protein Chemistry, San Diego, CA, Academic Press, pp 293-368. Acolbifene 2001
401. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Giguère, V., Tremblay, A., Tremblay, G. (2001) EM-652 (SCH 57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol., 79: 213-225. Acolbifene 2001
403. Labrie, F., Simard, A.R., Labrie, C., Bélanger, A. (2001) EM-652 (SCH57068) a pure SERM in the mammary gland and endometrium. Référence en Gynécologie Obstétrique, 8: 331-336. Acolbifene 2001
404. Pelletier, G., El Alfy, M., Labrie, C., Martel, C., Labrie, F. (2001) Effect of long-term treatment with the antiestrogen EM-652.HCl on pituitary estrogen receptor alpha and prolactin mRNA expression in intact, ovariectomized and GnRH-treated female rats. Neuroendocrinology, 74: 367-374. Acolbifene 2001
406. Sauvé, F., McBroom, L.D.B., Gallant, J., Moraitis, A.N., Labrie, F., Giguère, V. (2001) CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol. Cell. Biol, 21: 343-353. Acolbifene 2001
407. Couillard, S., Labrie, C., Gauthier, S., Mérand, Y., Singh, S.M., Candas, B., Labrie, F. (2000) Long-term inhibitory effect of the orally active and pure antiestrogen EM-800 on the growth of human breast cancer xenografts in nude mice. Int. J. Cancer, 85: 424-429. Acolbifene 2000
408. Labrie, C., Labrie, F., Bélanger, A., Simard, J., Luo, S., Martel, C. (2000) EM-652 (SCH 57068), a third generation SERM (selective estrogen receptor modulator), acting as pure antiestrogen in the mammary gland and endometrium, in: Coutinho, E.M. et Spinola, P., eds: Current Knowledge in Reproductive Medicine. Proceedings of the 10th World Congress on Human Reproduction, Salvador, Brazil, 4-8th May 1999, Elsevier Science B.V., pp 381-397. Acolbifene 2000
409. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Luu-The, V., Candas, B. (2000) Mechanisms of action of estrogens and antiestrogens, in: Aso, T., Yanaihara, T. et Fujimoto, S., eds: The Menopause at the Millenium: Proceedings of the 9th World Congress on the Menopause, October 17-21, 1999, Yokohama, Japan, Parthenon Publishing, pp 14-22. Acolbifene 2000
411. Martel, C., Picard, S., Richard, V., Bélanger, A., Labrie, C., Labrie, F. (2000) Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. J. Steroid Biochem. Mol. Biol., 74: 45-56. Acolbifene 2000
412. Picard, F., Deshaies, Y., Lalonde, J., Samson, P., Labrie, C., Bélanger, A., Labrie, F., Richard, D. (2000) Effects of the estrogen antagonist EM-652.HCl on energy balance and lipid metabolism in ovariectomized rats. Int. J. Obes. Relat. Metab. Disord., 24: 830-840. Acolbifene 2000
360. Sourla, A., Richard, V., Labrie, F., Labrie, C. (2000) Exclusive androgenic effect of dehydroepiandrosterone in sebaceous glands of rat skin. J. Endocrinol., 166: 455-462. Acolbifene 2000
416. Couillard, S., Gutman, M., Labrie, F., Candas, B., Labrie, C. (1999) Effect of the combined treatment with the pure antiestrogen EM-800 and radiotherapy on the growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 4857-4863. Acolbifene 1999
417. Gutman, M., Couillard, S., Labrie, F., Candas, B., Labrie, C. (1999) Effects of the antiestrogen EM-800 (SCH 57050) and cyclophosphamide alone and in combination on growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 5176-5180. Acolbifene 1999
61. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Lin, S.-X., Candas, B., Cusan, L. (1999) Impact de l'intracrinologie dans la thérapeutique et la prévention des cancers du sein et de la prostate et de la ménopause, in: Guérité, N. et Leclère, J., eds: Mises au point cliniques d'endocrinologie, nutrition et métabolisme 1999, Paris, France, Les Éditions de Médecine Pratique, pp 169-204. Acolbifene 1999
420. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Gauthier, S., Luu-The, V., Mérand, Y., Giguère, V., Candas, B., Luo, S., Martel, C., Singh, S.M., Fournier, M., Coquet, A., Richard, V., Charbonneau, R., Charpenet, G., Tremblay, A., Tremblay, G., Cusan, L., Veilleux, R. (1999) EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol., 69: 51-84. Acolbifene 1999
421. Labrie, F.; (1999). EM-652: a pure anti-estrogen discovered and developed in Canada. The best hope for breast cancer prevention and treatment. Can. Breast Cancer Network, 4: Vol. 4, p. 7. Acolbifene 1999
424. Tremblay, G.B., Tremblay, A., Labrie, F., Giguère, V. (1999) Dominant activity of activation function-1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor α⁄β heterodimeric complex. Mol. Cell. Biol., 19: 1919-1927. Acolbifene 1999
425. Couillard, S., Gutman, M., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (1998) Comparison of the effects of the antiestrogens EM-800 and Tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res., 58: 60-64. Acolbifene 1998
426. Couillard, S., Labrie, C., Bélanger, A., Candas, B., Pouliot, F., Labrie, F. (1998) Effect of dehydroepiandrosterone and the antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts. J. Natl. Cancer Inst., 90: 772-778. Acolbifene 1998
428. Luo, S., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (1998) Prevention of development of dimenthylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH 57050). Breast Cancer Res. Treat., 49: 1-11. Acolbifene 1998
429. Luo, S., Sourla, A., Labrie, C., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, F. (1998) Effect of twenty-four-week treatment with the antiestrogen EM-800 on estrogen-sensitive parameters in intact and ovariectomized mice. Endocrinology, 139: 2645-2656. Acolbifene 1998
430. Martel, C., Labrie, C., Bélanger, A., Gauthier, S., Mérand, Y., Li, X., Provencher, L., Candas, B., Labrie, F. (1998) Comparison of the effects of the new orally active antiestrogen EM-800 with ICI 182 780 and toremifene on estrogen-sensitive parameters in the ovariectomized mouse. Endocrinology, 139: 2486-2492. Acolbifene 1998
<< previous
| 1 | 2 next >>

Biography  |  Publications  |  Scientific Conferences  |  Selected Slide Presentations  |  Awards